Hormonal
Higher circulating levels of phospholipid metabolites, specifically choline, glycerophosphoethanolamine, and glycerophosphorylcholine (GPC), are associated with an insulin-sensitive phenotype in obese individuals, distinguishing them from obese insulin-resistant individuals.
This research suggests that for obese individuals, metabolic health (specifically insulin sensitivity) can be distinguished by blood levels of choline and related phospholipids. Higher levels of these metabolites are linked to a protective, insulin-sensitive state. This implies that metabolic health is not uniform across all obese individuals and may be assessed through specific biomarkers rather than weight alone.
Our results showed that phospholipid metabolites including choline, glycerophosphoethanolamine and glycerophosphorylcholine were significantly altered from OIS when compared with OIR and T2DM individuals... Figure 1 demonstrates higher levels of choline, glycophosphoethanolamine and GPC in OIS compared OIR + T2DM and lean groups.
Why this rating
The study is a pilot observational study with a relatively small sample size (n=107) and cross-sectional design, limiting causal interpretation.
Source
Metabolic signature of obesity-associated insulin resistance and type 2 diabetes
Haya Al‐Sulaiti et al. · Journal of Translational Medicine · 2019
DOI 10.1186/s12967-019-2096-8
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →